文献速递临床试验与 GCP流行病学与生物统计

阿哌沙班预防癌症患者静脉血栓栓塞

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
PubMed 文献 · N Engl J Med · 2018-12-04

AVERT试验为随机、安慰剂对照、双盲研究,评估阿哌沙班2.5 mg每日两次用于Khorana评分≥2、开始化疗的门诊癌症患者血栓预防。阿哌沙班组静脉血栓栓塞发生率为4.2%,安慰剂组为10.2%(HR 0.41;95%CI 0.26–0.65;P<0.001),但大出血发生率更高(3.5% vs 1.8%;HR 2.00;95%CI 1.01–3.95;P=0.046)。

要点

  • 对Khorana评分≥2且开始化疗的门诊癌症患者,阿哌沙班可显著降低静脉血栓栓塞风险。
  • 阿哌沙班2.5 mg每日两次与大出血风险升高相关,需权衡获益与出血风险。
  • 该研究为高危门诊癌症患者血栓预防提供了随机对照证据。

核心结论

  • 在Khorana评分≥2、开始化疗的门诊癌症患者中,阿哌沙班较安慰剂显著降低静脉血栓栓塞发生率,但大出血发生率更高。

研究设计与样本

  • 随机、安慰剂对照、双盲临床试验(AVERT,NCT02048865),574例患者随机分组,563例纳入改良意向治疗分析。
  • 纳入标准为活动性癌症、静脉血栓栓塞中高危(Khorana评分≥2)且开始化疗的门诊患者;阿哌沙班剂量为2.5 mg每日两次。
  • 主要疗效终点为180天随访期内客观记录的静脉血栓栓塞,主要安全终点为大出血。

主要发现

  • 静脉血栓栓塞在阿哌沙班组288例中发生12例(4.2%),安慰剂组275例中发生28例(10.2%)(HR 0.41;95%CI 0.26–0.65;P<0.001)。
  • 改良意向治疗分析中大出血阿哌沙班组10例(3.5%),安慰剂组5例(1.8%)(HR 2.00;95%CI 1.01–3.95;P=0.046)。
  • 治疗期间大出血阿哌沙班组6例(2.1%),安慰剂组3例(1.1%)(HR 1.89;95%CI 0.39–9.24)。

关键数值与推荐

  • Khorana评分范围为0至6分,评分越高静脉血栓栓塞风险越高,本研究纳入Khorana评分≥2的患者。
  • 主要疗效终点为180天随访期内客观记录的静脉血栓栓塞,主要安全终点为大出血。

临床怎么用

  • 对Khorana评分≥2且开始化疗的门诊癌症患者,可考虑阿哌沙班2.5 mg每日两次预防静脉血栓栓塞。
  • 用药前应评估出血风险,治疗期间关注大出血事件,结合患者个体情况权衡血栓预防的获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophylaxis. METHODS: We conducted a randomized, placebo-controlled, double-blind clinical trial assessing the efficacy and safety of apixaban (2.5 mg twice daily) for thromboprophylaxis in ambulatory patients with cancer who were at intermediate-to-high risk for venous thromboembolism (Khorana score, ≥2) and were initiating chemotherapy. The primary efficacy outcome was objectively documented venous thromboembolism over a follow-up period of 180 days. The main safety outcome was a major bleeding episode. RESULTS: Of the 574 patients who underwent randomization, 563 were included in the modified intention-to-treat analysis. Venous thromboembolism occurred in 12 of 288 patients (4.2%) in the apixaban group and in 28 of 275 patients (10.2%) in the placebo group (hazard ratio, 0.41; 95% confidence interval [CI], 0.26 to 0.65; P<0.001). In the modified intention-to-treat analysis, major bleeding occurred in 10 patients (3.5%) in the apixaban group and in 5 patients (1.8%) in the placebo group (hazard ratio, 2.00; 95% CI, 1.01 to 3.95; P = 0.046). During the treatment period, major bleeding occurred in 6 patients (2.1%) in the apixaban group and in 3 patients (1.1%) in the placebo group (hazard ratio, 1.89; 95% CI, 0.39 to 9.24). CONCLUSIONS: Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate-to-high-risk ambulatory patients with cancer who were starting chemotherapy. The rate of major bleeding episodes was higher with apixaban than with placebo. (Funded by the Canadian Institutes of Health Research and Bristol-Myers Squibb-Pfizer Alliance; AVERT ClinicalTrials.gov number, NCT02048865.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2018. PMID: 30511879. doi:10.1056/NEJMoa1814468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。